Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT01491074
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT01491074 -
2010-021953-37
-
- Other papers using this trial's data
- Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Norway
- Registry status
- Completed
Technical summary
Registry record NCT01491074. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction
- Condition
- Non-ST Elevation Myocardial Infarction
- Intervention (Drug)
- Tocilizumab 280 mg
- Intervention (Drug)
- NaCl 0.9% 100 ml
- Lead sponsor
- Oslo University Hospital
- Collaborator
- St. Olavs Hospital
- Collaborator
- South-Eastern Norway Regional Health Authority
- Collaborator
- University of Oslo
- Collaborator
- Norwegian University of Science and Technology
Record details
- Record id
cardio:ct-nct01491074- Content hash
5d8891fa5a92fbecef68084db99d96569dda660752f2ba0acf2b1464e31dab6d